{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Prime Medicine, Inc."},"Symbol":{"label":"Symbol","value":"PRME"},"Address":{"label":"Address","value":"21 ERIE STREET,120 EAST LIBERTY DRIVE, SUITE 400, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 564-0013"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs."},"CompanyUrl":{"label":"Company Url","value":"https://www.primemedicine.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ann L. Lee","title":"Chief Technical Officer"},{"name":"Jeremy Duffield","title":"Chief Scientific Officer"},{"name":"Keith M. Gottesdiener","title":"President, Chief Executive Officer & Director"},{"name":"Meredith Goldwasser","title":"Head-Strategy & Corporate Operations"},{"name":"Mohammed Asmal","title":"Senior Vice President & Head-Clinical"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}